Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – Melanoma and other skin tumours

5704 - Safety and Efficacy of TRIplet combination of Nivolumab (N) with Dabrafenib (D) and Trametinib (T) [TRIDeNT] in Patients (pts) with BRAF-mutated Metastatic Melanoma (MM): A Single Center Phase II Study

Date

28 Sep 2019

Session

Poster Discussion – Melanoma and other skin tumours

Presenters

Elizabeth Burton

Citation

Annals of Oncology (2019) 30 (suppl_5): v533-v563. 10.1093/annonc/mdz255

Authors

E.M. Burton1, R.N. Amaria2, I.C. Glitza3, M. Shephard3, A. Diab3, D. Milton4, S. Patel5, J. Mcquade6, M. Wong6, P. Hwu7, J. Wargo8, M.A. Davies3, H.A. Tawbi9

Author affiliations

  • 1 Surgical Oncology, UT MD Anderson Cancer Center, 77030 - Houston/US
  • 2 Melanoma Medical Oncology, The M. D. Anderson Cancer Center, 77030-3721 - Houston/US
  • 3 Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 4 Biostatistics, UT MD Anderson Cancer Center, 77030 - Houston/US
  • 5 Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 6 Melanoma Medical Oncology Department, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 7 Department Of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston/US
  • 8 Surgical Oncology, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 9 Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 77035 - Houston/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5704

Background

Although targeted therapies (TT) and immunotherapies (IMT) have improved survival for pts with BRAF V600 mutated stage IV MM, many pts progress and will ultimately die from this disease. Preclinical data has shown that BRAF inhibition (BRAFi) in BRAF-mutated tumors is associated with increased T cell infiltration, supporting the rationale for a clinical combinatorial approach with IMT. Although there are multicentered trials ongoing evaluating this combinatorial approach for pts with untreated MM, there are no approved therapies for pts after TT and IMT failure. Notably, patients with untreated brain metastases (BM) are often excluded from such trials. We hypothesized that N in combination with DT is safe and will demonstrate clinical activity in BRAF-mutated pts refractory to PD1 therapy and in pts with BM.

Methods

We report a single arm phase II study (NCT02910700) of NDT in pts with BRAF-mutated, unresectable stage III or stage IV MM. Prior IMT is allowed, but pts who have received BRAF/MEKi are ineligible. Pts with untreated BM and asymptomatic or mildly symptomatic/requiring stable or decreasing steroids (up to PO dexamethasone of 8 mg or equivalent) are also allowed. Pts received 3mg/kg Q2wks of N (later amended to 480 mg q4wks), 150mg BID of D and 2mg QD of T, all starting on Day 1. The primary objective of this study is to determine safety and efficacy (ORR by RECIST 1.1) of the NDT combination. This study is continuously monitored for safety and futility. Tissue and blood-based samples to assess for correlative studies are also collected.

Results

Following a 6 pts safety run-in which no DLTs were observed, 24 patients in total have received NDT – 18 of which were PD1 refractory. 6 pts have discontinued due to toxicities. 7 of the 18 PD1 refractory pts had untreated BM. Of the 19 total evaluable pts, 15 achieved PR and 2 CR (ORR 89%). 12 PD1 refractory were evaluable for response; 2 achieved CR and 10 PR (ORR 67%).

Conclusions

NDT is well-tolerated and shows promising clinical activity in pts with IMT refractory disease and with BM. Further investigation into the correlatives and mechanisms of action is warranted.

Clinical trial identification

NCT02910700.

Editorial acknowledgement

Legal entity responsible for the study

The University of Texas, MD Anderson Cancer Center.

Funding

Bristol-Myers Squibb.

Disclosure

R.N. Amaria: Research grant / Funding (institution): Merck. J. Wargo: Honoraria (self): BMS; Honoraria (self): Illumina; Advisory / Consultancy: GSK; Advisory / Consultancy: Roche/Genentech; Advisory / Consultancy: Novartis; Advisory / Consultancy: AstraZeneca. M.A. Davies: Advisory / Consultancy: Novartis; Advisory / Consultancy, Research grant / Funding (institution): Roche/Genentech; Advisory / Consultancy: BMS; Advisory / Consultancy, Research grant / Funding (institution): Sanofi Aventis; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Merck; Advisory / Consultancy: Vaccinex. H.A. Tawbi: Advisory / Consultancy: Novartis; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Celegene. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.